COVID

ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease

Retrieved on: 
Tuesday, January 10, 2023

WINSTON-SALEM, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the publication of the trial design and early data analysis from REGEN-003, a Phase 2 clinical study of Renal Autologous Cell Therapy (REACT®), in the Journal of Blood Purification. The paper, titled Renal Autologous Cell Therapy (REACT) in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis, was published online and will appear later this year in the print edition of the Journal (DOI: doi.org/10.1159/000527582).

Key Points: 
  • The paper, titled Renal Autologous Cell Therapy (REACT) in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis, was published online and will appear later this year in the print edition of the Journal (DOI: doi.org/10.1159/000527582 ).
  • “This is a high-risk patient population with seriously reduced kidney function.
  • At 15 months, two patients (20%) had preservation of their kidney function and had not advanced to renal replacement therapy.
  • We believe that REACT has the potential to have a significant, positive impact on patients’ health and quality of life.

H World Group Limited Announces Pricing of Public Offering of American Depositary Shares

Retrieved on: 
Tuesday, January 10, 2023

SHANGHAI, China, Jan. 10, 2023 (GLOBE NEWSWIRE) -- H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World” or the “Company”), a key player in the global hotel industry, today announced that the pricing of its underwritten public offering (the “Offering”) of 6,190,000 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US$42.0 per ADS.

Key Points: 
  • SHANGHAI, China, Jan. 10, 2023 (GLOBE NEWSWIRE) -- H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World” or the “Company”), a key player in the global hotel industry, today announced that the pricing of its underwritten public offering (the “Offering”) of 6,190,000 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US$42.0 per ADS.
  • In addition, the underwriters for this Offering have a 30-day option to purchase up to an aggregate of 928,500 additional ADSs from the Company.
  • and UBS Securities LLC are acting as joint underwriters for the Offering.
  • H World undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.

H World Group Limited Announces Proposed Public Offering of American Depositary Shares

Retrieved on: 
Tuesday, January 10, 2023

SHANGHAI, China, Jan. 10, 2023 (GLOBE NEWSWIRE) -- H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World” or the “Company”), a key player in the global hotel industry, today announced that it has commenced an underwritten public offering (the “Offering”) of US$260 million of American depositary shares of the Company (“ADSs”) in the United States, each representing ten ordinary shares of the Company.

Key Points: 
  • SHANGHAI, China, Jan. 10, 2023 (GLOBE NEWSWIRE) -- H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World” or the “Company”), a key player in the global hotel industry, today announced that it has commenced an underwritten public offering (the “Offering”) of US$260 million of American depositary shares of the Company (“ADSs”) in the United States, each representing ten ordinary shares of the Company.
  • The underwriters are expected to have a 30-day option to purchase up to US$39 million of additional ADSs from the Company.
  • The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed.
  • H World undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.

Sharps Technology Inc. to Introduce New Specialized Prefillable Syringe Systems in 2023

Retrieved on: 
Tuesday, January 10, 2023

NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces the advancement of the Company's specialized prefillable syringe ("PFS") system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina.

Key Points: 
  • Sharps announced a manufacturing and research partnership with Nephron Pharmaceuticals in November 2022 that will support the manufacturing of the Company's new innovative prefillable syringe systems, which will begin in the third quarter of 2023 in South Carolina.
  • Robert Hayes, Sharps Chief Executive Officer, commented: "Following years of research and development, Sharps is now in a position to commercialize and support the future of specialty syringe drug filling technology.
  • The opportunity to advance our product and manufacturing strategy to include high value prefillable syringe products will significantly accelerate our revenue growth for 2023 and beyond.
  • This is the reason why prefillable syringe systems are considered a high growth segment of the drug packaging market.

Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants

Retrieved on: 
Monday, January 9, 2023

Disruption of the spike protein to prevent viral entry into the host cells with a molecule that is already approved and deemed safe for human use could accelerate the development of a new treatment option for COVID patients.

Key Points: 
  • Disruption of the spike protein to prevent viral entry into the host cells with a molecule that is already approved and deemed safe for human use could accelerate the development of a new treatment option for COVID patients.
  • A copy of the publication can be found at https://www.biorxiv.org/content/10.1101/2023.01.06.522977v1.full#F7 .
  • The goal date for the FDA to provide its written responses is March 7, 2023.
  • The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.

ETC Announces Fiscal 2023 Third Quarter Results and Board of Director Appointment

Retrieved on: 
Monday, January 9, 2023

Net sales in the 2023 third fiscal quarter were $6.4 million, an increase of $2.0 million, or 45.7%, compared to 2022 third quarter net sales of $4.4 million.

Key Points: 
  • Net sales in the 2023 third fiscal quarter were $6.4 million, an increase of $2.0 million, or 45.7%, compared to 2022 third quarter net sales of $4.4 million.
  • Aerospace sales in 2023 third fiscal quarter accounted for 53% of overall sales, compared to 69% in third fiscal quarter 2022.
  • Further, domestic sales of 45% in 2023 third fiscal quarter were increased from 35% in third fiscal quarter of 2022.
  • Gross profit for the 2023 third fiscal quarter of $1.8 million increased from $0.7 million in the 2022 third fiscal quarter, an increase of $1.1 million, or 148.1%.

Selectis Health Reports Third Quarter 2022 Results

Retrieved on: 
Monday, January 9, 2023

Greenwood Village, Colorado, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Selectis Health, Inc. (OTC: GBCS) ("Selectis" or the "Company") is reporting financial and operating results for the third quarter ended September 30, 2022.

Key Points: 
  • Greenwood Village, Colorado, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Selectis Health, Inc. (OTC: GBCS) ("Selectis" or the "Company") is reporting financial and operating results for the third quarter ended September 30, 2022.
  • Third Quarter 2022 Summary (vs. Year-Ago Quarter) 1
    Revenue increased 31% to $9.6 million compared to $7.3 million.
  • “During the third quarter, we continued to advance our strategic initiatives and meaningfully increase our portfolio-wide patient census,” said Lance Baller, Chairman and CEO of Selectis.
  • Net loss in the third quarter of 2022 was $1.0 million or $(0.33) per share compared to a net loss of $0.06 million or $(0.02) per share in the year-ago quarter.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Veru Inc. (VERU) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Pending

Retrieved on: 
Monday, January 9, 2023

SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now .
  • VERU’s filings therefore concealed the true risks faced by the Company in gaining approval for its EUA request.
  • Investors learned the truth on Nov. 9, 2022, when Veru announced that the FDA advisory committee (“AdCom”) voted against approving sabizabulin under the agency’s EUA pathway.
  • If you invested in Veru and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .

Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting

Retrieved on: 
Monday, January 9, 2023

These data further confirm that adequate blood levels are achieved in COVID-19 patients without the need for Ritonavir, a CYP3A4 potent inhibitor, as a booster.

Key Points: 
  • These data further confirm that adequate blood levels are achieved in COVID-19 patients without the need for Ritonavir, a CYP3A4 potent inhibitor, as a booster.
  • This Phase 1b safety, PK and efficacy study in healthy volunteers and COVID patients was conducted in China.
  • “We are excited to see the similarities of PK in the China study and the Australian study.
  • The significant antiviral effectiveness and tolerability of OVYDSO in COVID patients suggests this compound will significantly benefit patients and will require no boosting with Ritonavir.

KBRA Releases Research – Waning COVID-Era Federal Dollars: Are State and Local Governments at Risk?

Retrieved on: 
Monday, January 9, 2023

KBRA releases research that examines how federal stimulus payments under three programs, in response to the COVID-19 disruption, have been utilized by state and local governments and the relation to credit risk as these payments subside.

Key Points: 
  • KBRA releases research that examines how federal stimulus payments under three programs, in response to the COVID-19 disruption, have been utilized by state and local governments and the relation to credit risk as these payments subside.
  • The measures resulted in a substantial infusion of funds for states, counties, cities, transit systems, and airports, which offset potential operating deficits and tempered credit quality impacts, while allowing time for economic recovery.
  • While the primary focus was on replacement of lost revenue, federal funds have been used in varied ways, including expenditures not related to the pandemic.
  • Entities that established new programs with grant funds may face a fiscal cliff if dedicated replacement funding is not identified.